Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.5K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Machine Learning With Optical Coherence Tomography for Glaucoma Diagnosis.

Journal of glaucoma·2026
Same author

Comparative Outcomes Between Micropulse and Slow-Coagulation Transscleral Cyclophotocoagulation in Eyes With Good Visual Acuity.

Journal of glaucoma·2026
Same author

Outcomes of strabismus surgery in patients with cerebral palsy.

Strabismus·2026
Same author

Editorial: Imaging in glaucoma.

Frontiers in medicine·2026
Same author

Outcomes of strabismus surgery in patients with Down syndrome.

Arquivos brasileiros de oftalmologia·2025
Same author

Selective laser trabeculoplasty positively impacts long-term intraocular pressure fluctuation in untreated open-angle glaucoma patients.

Lasers in medical science·2025

Related Experiment Video

Updated: Mar 11, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.9K

Neovascular glaucoma: a review.

Gustavo B Rodrigues1, Ricardo Y Abe1, Camila Zangalli1

  • 1Department of Ophthalmology, Faculdade de Ciências Médicas - UNICAMP, University of Campinas, Caixa Postal - 6111, Campinas, SP 13083-970 Brazil.

International Journal of Retina and Vitreous
|November 30, 2016
PubMed
Summary
This summary is machine-generated.

Neovascular glaucoma (NVG) is a severe secondary glaucoma caused by abnormal blood vessel growth. Early diagnosis and treatment, including anti-VEGF therapies, are crucial for managing intraocular pressure and preserving vision.

Keywords:
Anti-VEGFCentral retinal vein occlusionDiabetesNeovascular glaucomaRefractory

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Related Experiment Videos

Last Updated: Mar 11, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential
07:11

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

6.9K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.7K

Area of Science:

  • Ophthalmology
  • Vascular Biology
  • Glaucoma Research

Background:

  • Neovascular glaucoma (NVG) is a secondary glaucoma with a poor visual prognosis.
  • It results from new blood vessel growth (neovascularization) on the iris and iridocorneal angle, obstructing aqueous humor outflow and increasing intraocular pressure.
  • NVG is typically caused by posterior segment ischemia, often linked to proliferative diabetic retinopathy or central retinal vein occlusion.

Approach:

  • Diagnosis involves slit lamp examination of the iris, iridocorneal angle, and retina to detect neovascularization.
  • Understanding the role of angiogenic factors like vascular endothelial growth factor (VEGF) and anti-angiogenic factors is key.
  • Treatment strategies have evolved from traditional panretinal photocoagulation to newer approaches.

Key Points:

  • Neovascularization is driven by an imbalance between pro-angiogenic and anti-angiogenic factors.
  • Early detection can prevent goniosynechia and subsequent intraocular pressure elevation.
  • Intravitreal anti-VEGF therapies are increasingly investigated for NVG management.

Conclusions:

  • NVG management requires addressing the underlying ischemic cause and controlling intraocular pressure.
  • While panretinal photocoagulation was historical standard, anti-VEGF therapies offer a promising alternative.
  • Medical management with hypotensive drops, laser, and surgical procedures are employed based on severity.